tiprankstipranks
Trending News
More News >
Celon Pharma SA (DE:8RP)
FRANKFURT:8RP
Germany Market
Advertisement

Celon Pharma SA (8RP) Financial Statements

Compare
2 Followers

Celon Pharma SA Financial Overview

Celon Pharma SA's market cap is currently €305.28M. The company's EPS TTM is €; its P/E ratio is 73.28; and it has a dividend yield of 0.33%. Celon Pharma SA is scheduled to report earnings on May 21, 2025, and the estimated EPS forecast is €―. See an overview of income statement, balance sheet, and cash flow financials.
Dec 24Dec 23Dec 22Dec 21Dec 20
Income Statement
Total Revenuezł 176.62Mzł 213.92Mzł 161.91Mzł 169.56Mzł 139.27M
Gross Profitzł 113.45Mzł 147.10Mzł 95.45Mzł 107.84Mzł 107.26M
Operating Incomezł -36.81Mzł -27.24Mzł -34.73Mzł -13.67Mzł 36.82M
EBITDAzł 14.96Mzł 32.71Mzł 9.32Mzł 27.81Mzł 30.37M
Net Incomezł -34.45Mzł -28.12Mzł -39.28Mzł -11.61Mzł 21.50M
Balance Sheet
Cash & Short-Term Investmentszł 56.52Mzł 114.54Mzł 164.62Mzł 227.55Mzł 43.98M
Total Assetszł 543.79Mzł 569.31Mzł 608.93Mzł 707.14Mzł 703.64M
Total Debtzł 16.93Mzł 25.59Mzł 26.82Mzł 14.92Mzł 23.07M
Net Debtzł 8.65Mzł -6.77Mzł -56.08Mzł -132.88Mzł -20.91M
Total Liabilitieszł 98.59Mzł 123.75Mzł 129.29Mzł 153.14Mzł 268.97M
Stockholders' Equityzł 445.21Mzł 445.56Mzł 479.65Mzł 554.00Mzł 434.67M
Cash Flow
Free Cash Flowzł -34.13Mzł -41.13Mzł -38.61Mzł 2.60Mzł -28.26M
Operating Cash Flowzł -11.34Mzł -8.31Mzł -4.70Mzł 43.95Mzł 70.90M
Investing Cash Flowzł -7.49Mzł -21.64Mzł -31.47Mzł -121.05Mzł -98.53M
Financing Cash Flowzł 13.32Mzł -20.59Mzł -28.72Mzł 180.91Mzł 4.91M
Currency in PLN

Celon Pharma SA Earnings and Revenue History

Celon Pharma SA Debt to Assets

Celon Pharma SA Cash Flow

Celon Pharma SA Forecast EPS vs Actual EPS

Currently, no data available
Please return soon. This page is being updated.
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis